About: Four years of experience with administration of the recombinant factor VIII in children     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • The safety of therapeutics for haemophilia A patients has improved markedly with the developmentand commercial production of rFVIII products. Currently the most serious and challenging complication is the development of inhibitory antibodies against factor VIII. Risk factors for the development of an inhibitor include: 1. previous exposure to factor VIII replacement products and packed red cells transfusions, 2. severe haemophilia 3. Family history of inhibitors, 4. African ethnicity, 5. Certain mutations of the factor VIII gene, 6. Immune system activation i.e. immunization and 7. early age at first factor replacement therapy.
  • The safety of therapeutics for haemophilia A patients has improved markedly with the developmentand commercial production of rFVIII products. Currently the most serious and challenging complication is the development of inhibitory antibodies against factor VIII. Risk factors for the development of an inhibitor include: 1. previous exposure to factor VIII replacement products and packed red cells transfusions, 2. severe haemophilia 3. Family history of inhibitors, 4. African ethnicity, 5. Certain mutations of the factor VIII gene, 6. Immune system activation i.e. immunization and 7. early age at first factor replacement therapy. (en)
Title
  • Four years of experience with administration of the recombinant factor VIII in children
  • Four years of experience with administration of the recombinant factor VIII in children (en)
skos:prefLabel
  • Four years of experience with administration of the recombinant factor VIII in children
  • Four years of experience with administration of the recombinant factor VIII in children (en)
skos:notation
  • RIV/00843989:_____/09:00100631!RIV10-MZ0-00843989
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • V
http://linked.open...iv/cisloPeriodika
  • Suppl.1
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 315468
http://linked.open...ai/riv/idVysledku
  • RIV/00843989:_____/09:00100631
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • haemophilia A; treatment; recombinant factor VIII; Advate; children (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • DE - Spolková republika Německo
http://linked.open...ontrolniKodProRIV
  • [705CF34D31E1]
http://linked.open...i/riv/nazevZdroje
  • Hämostaseologie
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 29
http://linked.open...iv/tvurceVysledku
  • Blažek, Bohumír
  • Kuhn, Tomáš
  • Ptoszková, Hana
http://linked.open...ain/vavai/riv/wos
  • 000272214600034
issn
  • 0720-9355
number of pages
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 106 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software